Great Lakes Pharmaceuticals, Inc. Announces Initiation of Clinical Study for Antimicrobial Lock Solution, B-Lock™.
Beachwood, July 24, 2012 – Great Lakes Pharmaceuticals, Inc. announced today the initiation of the clinical study of the first Company product, the antimicrobial lock solution, B-Lock™. The prospective, randomized, active control clinical investigation is being conducted in 22 clinical sites in Hungary and Poland and will involve up to 400 patients on renal dialysis who require a central venous catheter for vascular access. The Company expects a wealth of clinical safety and efficacy data based on up to 45,000 catheter-days observations. If successful, the clinical data will be used for CE Mark approval in the European Union. More…PDF(56Kb) [...]
Great Lakes Pharmaceuticals, Inc. Announces $2.4 Million Equity Financing
Cleveland, OH, May 1, 2008 – Great Lakes Pharmaceuticals, Inc. announced today the completion of Series A $2.4 million equity financing led by Ohio investment funds including the North Coast Angel Fund JumpStart Inc., Everett Partners, Ltd, Ohio TechAngel Fund and Case Technology Ventures. The Company intends to use the funds to finalize the pre-clinical development and initiate pivotal clinical study of B-Lock™, an antimicrobial and heparin-free antithrombotic catheter lock solution. More…PDF(42Kb) [...]
Great Lakes Pharmaceuticals, Inc. Announces the Signing of Exclusive License Agreements
Cleveland, Ohio, (January 30, 2008) – Great Lakes Pharmaceuticals, Inc. announced today that it has entered into exclusive license agreements with The Board of Regents of The University of Texas System, acting on behalf of The University of Texas M. D. Anderson Cancer Center (“UTMDACC”), and Wake Forest University Health Sciences (“WFUHS”). More…PDF(43Kb) [...]